Correspondence

A substitute for “small airway disease”?

Sir,—I was very interested by the editorial of Drs CM Fletcher and NB Pride “revisiting” the definitions of emphysema, bronchitis, and airflow obstruction 25 years after the CIBA Guest Symposium (February 1984, p 81). There is no doubt for me that “the term chronic bronchitis should be used only to denote chronic or recurrent bronchial hypersecretion.” Ten years ago I was among the Romanian pulmonologists stressing the ambiguous character of the term chronic bronchitis and calling for its re-definition. With regard to “non-emphysematous irreversible airway obstruction,” although agreeing that “small airways disease” is unsuitable, I was somewhat surprised to see that “peripheral airway obstruction” was not considered (and discussed) as an alternative. “Peripheral” could be defined as the airways distal to the XIII–XIVth generation according to Weibel. The term is currently used in French publications.

I am unable to say who and when used this term for the first time, but by 1970 Macklem and coworkers studied the “stability of peripheral airways,” and in 1973 the same team evaluated the changes in particulate deposition in the lung with “peripheral airway obstruction.”

Why not “peripheral airway obstruction” then?

DB TECELESCU
INSERM Unité 14, CHU Brabois, 54511 Vandoeuvre, Nancy, FRANCE


* This letter was sent to the authors, who reply below.

Sir,—We are grateful to Dr Teculescu for his support for our insistence that British authors and chest physicians should confine their use of the term chronic bronchitis to chronic or recurrent bronchial mucous hypersecretion.

We agree that the term peripheral airway obstruction is an improvement on “small airway disease,” but it does not distinguish between narrowing due to primary disease of the airway wall or lumen and narrowing which is secondary to the loss of airway distending forces and lung recoil that accompanies emphysema. In the latter case there may be no pathological change in the airway wall or lumen. As we were seeking a term to describe non-emphysematous irreversible obstructive disease of the peripheral airways themselves, we preferred the term obstructive bronchiolitis, which, although not quite accurate anatomically, does indicate the presence of inflammatory change in the airway itself. We would be happier to use peripheral air...

Sir,—I was very interested by the editorial of Drs CM Fletcher and NB Pride “revisiting” the definitions of emphysema, bronchitis, and airflow obstruction 25 years after the CIBA Guest Symposium (February 1984, p 81). There is no doubt for me that “the term chronic bronchitis should be used only to denote chronic or recurrent bronchial hypersecretion.” Ten years ago I was among the Romanian pulmonologists stressing the ambiguous character of the term chronic bronchitis and calling for its re-definition. With regard to “non-emphysematous irreversible airway obstruction,” although agreeing that “small airways disease” is unsuitable, I was somewhat surprised to see that “peripheral airway obstruction” was not considered (and discussed) as an alternative. “Peripheral” could be defined as the airways distal to the XIII–XIVth generation according to Weibel. The term is currently used in French publications.

I am unable to say who and when used this term for the first time, but by 1970 Macklem and coworkers studied the “stability of peripheral airways,” and in 1973 the same team evaluated the changes in particulate deposition in the lung with “peripheral airway obstruction.”

Why not “peripheral airway obstruction” then?

DB TECELESCU
INSERM Unité 14, CHU Brabois, 54511 Vandoeuvre, Nancy, FRANCE


* This letter was sent to the authors, who reply below.

Standardised lung function testing

Sir,—In your editorial ‘Standardised lung function testing’ (December 1984;39:881–6) Dr G Laszlo summarises the consequences of changing from the reference values given by Cotes1 to the European Coal and Steel Community (ECSC) figures.2 Overall he considers the changes are relatively slight. From the table, however, changes for transfer coefficient (KCO) of + 0.4 mmol min⁻¹ kPa⁻¹ l⁻¹ for men and + 0.25 to + 0.38 for women represent standard deviation changes of 1.48 for males and 1.9–1.25 for females. These are considerable deviations and would materially affect the reporting of KCO lung function data in most UK laboratories adopting the ECSC figures. Is there an explanation for these apparently large differences in transfer coefficient formulae?

ALAN J WILLIAMS
Department of Respiratory Medicine, Royal Liverpool Hospital, Liverpool L7 8XP


This letter was sent to Dr Laszlo, who replies below.

Sir,—I was very interested by the editorial of Drs CM Fletcher and NB Pride “revisiting” the definitions of emphysema, bronchitis, and airflow obstruction 25 years after the CIBA Guest Symposium (February 1984, p 81). There is no doubt for me that “the term chronic bronchitis should be used only to denote chronic or recurrent bronchial hypersecretion.” Ten years ago I was among the Romanian pulmonologists stressing the ambiguous character of the term chronic bronchitis and calling for its re-definition. With regard to “non-emphysematous irreversible airway obstruction,” although agreeing that “small airways disease” is unsuitable, I was somewhat surprised to see that “peripheral airway obstruction” was not considered (and discussed) as an alternative. “Peripheral” could be defined as the airways distal to the XIII–XIVth generation according to Weibel. The term is currently used in French publications.

I am unable to say who and when used this term for the first time, but by 1970 Macklem and coworkers studied the “stability of peripheral airways,” and in 1973 the same team evaluated the changes in particulate deposition in the lung with “peripheral airway obstruction.”

Why not “peripheral airway obstruction” then?

DB TECELESCU
INSERM Unité 14, CHU Brabois, 54511 Vandoeuvre, Nancy, FRANCE


* This letter was sent to the authors, who reply below.

Standardised lung function testing

Sir,—In your editorial ‘Standardised lung function testing’ (December 1984;39:881–6) Dr G Laszlo summarises the consequences of changing from the reference values given by Cotes1 to the European Coal and Steel Community (ECSC) figures.2 Overall he considers the changes are relatively slight. From the table, however, changes for transfer coefficient (KCO) of + 0.4 mmol min⁻¹ kPa⁻¹ l⁻¹ for men and + 0.25 to + 0.38 for women represent standard deviation changes of 1.48 for males and 1.9–1.25 for females. These are considerable deviations and would materially affect the reporting of KCO lung function data in most UK laboratories adopting the ECSC figures. Is there an explanation for these apparently large differences in transfer coefficient formulae?

ALAN J WILLIAMS
Department of Respiratory Medicine, Royal Liverpool Hospital, Liverpool L7 8XP


* This letter was sent to Dr Laszlo, who replies below.